Back Foley Viewpoints How FDA Differs From CMS in Clinical Lab Test Oversight March 14, 2013 Share on LinkedInShare on TwitterPrintShare by EmailShare Back to top Partner Antoinette Konski authored an article that appeared in Law360 on March 14, 2013 titled “How FDA Differs From CMS In Clinical Lab Test Oversight.” Author(s) Antoinette F. Konski akonski@foley.com Silicon Valley 650.251.1129 Related Insights View All Posts July 25, 2025 Foley Viewpoints Thorny Laws That ICHRA Vendors Should Consider, Part Three: FinTech Edition We continue our series on the legal and regulatory challenges facing individual coverage health reimbursement arrangements (ICHRAs); this… July 24, 2025 Manufacturing Industry Advisor Foley Automotive Update Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term… July 23, 2025 Foley Viewpoints The One Big Beautiful Bill and Workplace Immigration Enforcement The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
